ADIL - CIK 0001513525
The table below shows ADIAL PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.49M | -$6.92M | -$6.81M | -$11.19M | -$11.95M | -$7.63M |
| Capital expenditure | - | - | - | - | $64.61K | - |
| Investing cash flow | $150.00K | - | $1.50M | - | -$34.02K | -$350.00K |
| Dividends paid | - | - | - | - | - | - |
ADIAL PHARMACEUTICALS, INC. reported operating cash flow of -$6.49M for fiscal year 2025. That is up 6.2% from -$6.92M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$494.86K (FY 2017) to -$6.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | $1.66K | - | - | - |
| Financing cash flow | $8.47M | $7.85M | $4.13M | $9.13M | $13.64M | $5.61M |